^
BIOMARKER:

PIK3CA H1047R

i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Entrez ID:
Related biomarkers:
PIK3CA H1047R
HCC
palbociclib + alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA H1047R
HCC
alpelisib + TAK-228
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA H1047R
HCC
alpelisib
Resistant: D – Preclinical
Cell Death Dis - 1 week
PIK3CA H1047R
CRC
cetuximab
Resistant: C3 – Early Trials
PIK3CA H1047R
HER2 Positive Breast Cancer
PF-05212384 + Herzuma (trastuzumab biosimilar)
Sensitive: C3 – Early Trials
PIK3CA H1047R
NSCLC
trametinib + dabrafenib
Sensitive: C3 – Early Trials
PIK3CA H1047R
Breast Cancer
TAS-117
Sensitive: C3 – Early Trials
PIK3CA H1047R
Melanoma
dabrafenib
Sensitive: C4 – Case Studies
PIK3CA H1047R
HER2 Positive Breast Cancer
everolimus
Sensitive: C4 – Case Studies
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
PIK3CA H1047R
Salivary Gland Cancer
vandetanib
Sensitive: C4 – Case Studies
PIK3CA H1047R
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
PIK3CA H1047R
SCCHN
trametinib
Sensitive: D – Preclinical
PIK3CA H1047R
Endometrial Cancer
MEN1611
Sensitive: D – Preclinical
PIK3CA H1047R
CRC
MEN1611
Sensitive: D – Preclinical
PIK3CA H1047R
Breast Cancer
trastuzumab + lapatinib
Resistant: D – Preclinical
PIK3CA H1047R
Breast Cancer
trastuzumab + MEN1611
Sensitive: D – Preclinical
PIK3CA H1047R
Breast Cancer
GDC-0941
Sensitive: D – Preclinical
PIK3CA H1047R
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: D – Preclinical
PIK3CA H1047R
Head and Neck Cancer
alpelisib
Sensitive: D – Preclinical
PIK3CA H1047R
Ovarian Cancer
MEN1611
Sensitive: D – Preclinical
PIK3CA H1047R
Ovarian Cancer
LX-086
Sensitive: D – Preclinical
PIK3CA H1047R
Head and Neck Cancer
SHR-A1307
Sensitive: D – Preclinical
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
PIK3CA H1047R
HER2 Negative Breast Cancer
LX-086
Sensitive: D – Preclinical
PIK3CA H1047R
SCCHN
GDC-0941
Resistant: D – Preclinical
PIK3CA H1047R
SCCHN
BMS-722782
Resistant: D – Preclinical
PIK3CA H1047R
SCCHN
PF-3845
Resistant: D – Preclinical
PIK3CA H1047R
SCCHN
PF-05212384
Sensitive: D – Preclinical
PIK3CA H1047R
SCCHN
cetuximab
Resistant: D – Preclinical
PIK3CA H1047R
SCCHN
RTB101
Sensitive: D – Preclinical
PIK3CA H1047R
Thyroid Gland Carcinoma
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
PIK3CA H1047R
SCCHN
GDC-0032
Sensitive: D – Preclinical
PIK3CA H1047R
SCCHN
cetuximab + RTB101
Sensitive: D – Preclinical